BIOPSYCHOSOCIAL APPROACHES TO OBSESSIVE-COMPULSIVE, BODY IMAGE AND EATING DISORDERS
Dr Nicola Acevedo, Neuroscientist and Research Fellow
Swinburne University of Technology, Melbourne, Australia
& Consultant, Neurotech Insights, Melbourne, Australia &
Director, BioAutism, Melbourne, Australia & Vice-President
Australasian Brain Stimulation Society
RESEARCHER PROFILE
Filmed in Melbourne, Australia | December 2025
Dr Nicola Acevedo is a Neuroscientist and Research Fellow with extensive expertise in developing novel therapeutics for neurological and psychiatric disorders, contributing to more than ten clinical trials. She specialises in brain stimulation and psychedelic treatments for obsessive-compulsive disorder (OCD) and related conditions, with a strong commitment to advancing personalised, evidence-based neurobiological therapies for severe psychiatric illness. Her approach integrates biopsychosocial and person-centred principles to improve treatment access and mental health outcomes.
Nicola completed her PhD on deep brain stimulation for treatment-refractory OCD- described as a “tour de force”- producing eight first-author peer-reviewed publications and multiple international collaborations and papers. She now leads research in psilocybin-assisted psychotherapy for OCD, body dysmorphic disorder, and anorexia nervosa. Her work has been presented at leading international forums including Oxford and Harvard University, and the Royal Australian and New Zealand College of Psychiatrists Congress.
Alongside her research, Nicola holds leadership positions across brain stimulation, OCD, and ethics committees, serves on a peer review board, and is Director of the charity BioAutism Ltd. She also provides mentorship and supervision, with a commitment to supporting junior researchers. Her contributions have been recognised with the Early Career Researcher (ECR) Excellence Award from Biological Psychiatry Australia. As an ECR, Nicola is driven by the potential to innovate and make an impact in national mental health services.
Source: Supplied
https://orcid.org/0000-0003-3059-3620
-
Better biomarkers for predicting the incidence of having atherosclerosis and heart attack
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
-
Digital Biomarkers and AI for Optimal Diagnosis, Treatment, and Decision-Making
Associate Professor Johan Verjans is a clinician-scientist with a strong focus on cross-disciplinary translational research. In his role as Deputy Director at the Australian Institute for Machine Learning (AIML)—one of the world’s premier machine learning institutes, with over 200 researchers—and as Group Leader of Artificial Intelligence at the South Australian Health and Medical Research Institute (SAHMRI), he integrates his expertise in molecular medicine, clinical research, and advanced imaging with machine learning applications. This unique combination enables him to drive the translation of cutting-edge AI research into practical medical applications. He works with global teams from multinationals on AI problems.
-
Trials in treating STIs, vaccines and lipid lowering medications
Since joining Paratus Clinical Research in 2022, Dr Pi Lip Seet has served as both Principal Investigator and Sub-Investigator across Phase I–IV industry-sponsored clinical trials. His research experience spans vaccines, immunology, cardiovascular and endocrine disease, respiratory medicine, gastroenterology, pain management, sleep medicine and adult psychiatry. He has been involved in multiple vaccine development programs, including RSV, influenza, COVID-19, herpes zoster and pneumococcal studies.
